NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Price & Overview
OSL:NYKD • NO0010714785
Current stock price
The current stock price of NYKD.OL is 3.135 NOK. Today NYKD.OL is down by -1.42%. In the past month the price increased by 5.35%. In the past year, price increased by 27.74%.
NYKD.OL Key Statistics
- Market Cap
- 1.024B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.35
- Dividend Yield
- 31.40%
NYKD.OL Stock Performance
NYKD.OL Stock Chart
NYKD.OL Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to NYKD.OL. When comparing the yearly performance of all stocks, NYKD.OL turns out to be only a medium performer in the overall market: it outperformed 61.41% of all stocks.
NYKD.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL. While NYKD.OL seems to be doing ok healthwise, there are quite some concerns on its profitability.
NYKD.OL Earnings
NYKD.OL Forecast & Estimates
7 analysts have analysed NYKD.OL and the average price target is 4.59 NOK. This implies a price increase of 46.41% is expected in the next year compared to the current price of 3.135.
For the next year, analysts expect an EPS growth of -114.29% and a revenue growth -100% for NYKD.OL
NYKD.OL Groups
Sector & Classification
NYKD.OL Financial Highlights
Over the last trailing twelve months NYKD.OL reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS increased by 68.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.25% | ||
| ROE | -13.37% | ||
| Debt/Equity | 0.01 |
NYKD.OL Ownership
NYKD.OL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 29.27 | 41.518B | ||
| ARGX | ARGENX SE | 29.23 | 41.431B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.62B | ||
| 2X1 | ABIVAX SA | N/A | 7.62B | ||
| ABVX | ABIVAX SA | N/A | 7.612B | ||
| GXE | GALAPAGOS NV | N/A | 1.607B | ||
| GLPG | GALAPAGOS NV | N/A | 1.605B | ||
| NANO | NANOBIOTIX | N/A | 1.361B | ||
| PHGN | PHARMING GROUP NV | 45.38 | 1.009B | ||
| PHARM | PHARMING GROUP NV | 47.07 | 1.004B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 946.39M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 932.473M | ||
| IVA | INVENTIVA SA | N/A | 907.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Oslo Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About NYKD.OL
Company Profile
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 59 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
Company Info
IPO: 2020-01-27
NYKODE THERAPEUTICS ASA
Oslo Science Park, Gaustadalleen 21
Oslo OSLO NO
Employees: 59
Phone: 4722958193
NYKODE THERAPEUTICS ASA / NYKD.OL FAQ
What does NYKODE THERAPEUTICS ASA do?
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 59 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
What is the stock price of NYKODE THERAPEUTICS ASA today?
The current stock price of NYKD.OL is 3.135 NOK. The price decreased by -1.42% in the last trading session.
Does NYKODE THERAPEUTICS ASA pay dividends?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a dividend yield of 31.4%. The yearly dividend amount is currently 0.92.
How is the ChartMill rating for NYKODE THERAPEUTICS ASA?
NYKD.OL has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of NYKD stock?
NYKODE THERAPEUTICS ASA (NYKD.OL) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for NYKD stock?
NYKODE THERAPEUTICS ASA (NYKD.OL) currently has 59 employees.
What is the market capitalization of NYKD stock?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a market capitalization of 1.02B NOK. This makes NYKD.OL a Small Cap stock.